Analysts Notes: New Report - Market Barriers Have a Small but Significant Impact on Melanoma Prescriptions

Two reports out from FirstView are shedding light on the way market barriers — factors unrelated to safety and efficacy — affect the way oncologists prescribe treatments for melanoma in the US and the EU5 countries (France, Germany, Italy, Spain and the UK).

Market barriers include factors such as, cost, market access, patient preferences, guidelines and recommendations, and more. FirstView's Market Access Impact: Melanoma [2018] reports for the US and EU5 examine the effects of seven such barriers on Cotellic, Imlygic, Keytruda, Mekinist, Opdivo, Tafinlar, Yervoy and Zelboraf. Both reports are based on surveys with practicing oncologists.

In the US and EU5, prescribing rates for melanoma treatments are moderately high, perhaps reflecting the challenging market access environment in each region. In both regions, only 4/8 brands are prescribed by 70 percent or more of physicians, with some only being prescribed by less than 30 percent of physicians.

The US and Europe also show similarities when it comes to brand awareness and where the impact of eliminating barriers would be most acutely felt. For example, in both regions doctors have good awareness of all surveyed brands, and similar numbers of doctors from both regions say that they would not prescribe certain brands.

Despite there being similarities between the two regions in terms of the most common barrier experienced by physicians, differences emerge when you look at the 2nd, 3rd and 4th most common barriers. By analysing these differences, companies will be able to develop robust regional market access strategies.

Full reports available from FirstView

These insights, along with the full survey results are included in in FirstView Market Access Impact: Melanoma [2018] for the US and EU5 markets, available for immediate download in the FirstView reports store.

Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.